A Randomized, Double-Blind, Placebo-Controlled, 12-Week Study of the Safety and Efficacy of REGN727 in Patients With Heterozygous Familial Hypercholesterolemia

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, 12-Week Study of the Safety and Efficacy of REGN727 in Patients With Heterozygous Familial Hypercholesterolemia

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2017

At a glance

  • Drugs Alirocumab (Primary)
  • Indications Hyperlipoproteinaemia type IIa
  • Focus Therapeutic Use
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 07 Feb 2017 Pooled analysis (n=5234) of 14 trials assessing safety of very low low-density lipoprotein cholesterol levels with alirocumab, published in the Journal of the American College of Cardiology
    • 06 Jan 2017 Results of a pooled target mediated drug disposition population pharmacokinetics analysis of Alirocumab from this and 12 other studies (n=2870), published in the Clinical Pharmacokinetics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top